Renovaro Biosciences (RENB)

Search documents
Renovaro Biosciences (RENB) - 2021 Q1 - Quarterly Report
2020-11-12 22:28
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 45-2259340 (State or other ju ...
Renovaro Biosciences (RENB) - 2020 Q4 - Annual Report
2020-09-23 21:24
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-54478 ENOCHIAN BIOSCIENCES INC. (Name of registrant in its charter) | Delaware | 45-2559340 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | i ...
Renovaro Biosciences (RENB) - 2020 Q3 - Quarterly Report
2020-05-11 20:33
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the S ...
Renovaro Biosciences (RENB) - 2020 Q2 - Quarterly Report
2020-02-10 22:17
Commission file number 000-54478 U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Enochian Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 45-2259340 (State or other jur ...
Renovaro Biosciences (RENB) - 2020 Q1 - Quarterly Report
2019-11-13 22:22
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delaware | 45-2259340 | | --- | --- ...
Renovaro Biosciences (RENB) - 2019 Q4 - Annual Report
2019-09-27 22:11
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2019 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission file number 000-54478 ENOCHIAN BIOSCIENCES, INC. (Name of registrant in its charter) Delaware 45-2559340 (State or other jurisdiction of incorporation or organization) (I.R.S. Employ ...
Renovaro Biosciences (RENB) - 2019 Q3 - Quarterly Report
2019-05-16 10:12
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 001-38758 Enochian Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delaware | 45-2259340 | | --- | --- | | ...
Renovaro Biosciences (RENB) - 2019 Q2 - Quarterly Report
2019-02-13 22:07
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FORM 10-Q For the quarterly period ended December 31, 2018 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ Commission file number 000-54478 Enochian Biosciences, Inc. (Exact name of registrant as specified in its charter) | Delaware | 45-2259340 | | --- | --- | ...